Peroxisome proliferator-activated receptors (Ppars): A target with a broad therapeutic potential for human diseases: An overview

Pharmacologyonline

Volumn 2, Issue , 2011, Pages 58-89

  Singh, Manish Pal ^a   Pathak, Devendra ^a   Sharma, Gyanendra K ^a   Sharma, C S ^b  

^a NH 2   (India)

^b BN College of Pharmacy   (India)

Author keywords

Metabolic diseases; Nuclear hormone receptor; PPAR ligands; PPARs

Indexed keywords

EID: 84885899635     PISSN: None     EISSN: 18278620     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Barnstable C.J, Tombran-Tink J. Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Prog Retin Eye Res. 2004;23:561–77.
2. Kota BP, Huang THW, Roufgalis BD. An overview on biological mechanisms of PPARs. Pharm Res. 2005;51:85–94.
3. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark E, Chambon P, Evans RM. The nuclear receptor superfamily: the second decade. Cell. 1995;83:835– 839.
4. Issemann I, Prince RA, Tugwood JD, Green S. The peroxisome proliferator-activated receptor: retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol. 1993;11:37– 47.
5. Namba T, Oida H, Sugimoto Y, Kakizuka A, Negishi M, Ichikawa A, Narumiya S. cDNA cloning of a mouse prostacyclin receptor: Multiple signaling pathways and expression in thymic medulla. J Biol Chem.1994;269:9986 –9992.
6. Pola R, Gaetani E, Flex A, Aprahamian TR, Bosch-Marce M, Losordo DW, Smith RC, Pola P. Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors. J Mol Cell Cardiol. 2004;36:363–370.
7. He T, Lu T, d’Uscio LV, Lam C-F, Lee H-C, Katusic ZS. Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells. Circ Res. 2008;103:80–88.
8. B. Brunmair et al. Activation of PPAR-δ in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids. Diabetologia. 2006:49:11: 2713–22.
9. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006:58: 4:726–41.
10. Rosen ED, Spiegelman BM. PPAR γ: a nuclear regulator of metabolism, differentiation and cell growth. J Bio Chem. 2001;276:37731-4.
11. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPAR α activators inhibit cytokine induced vascular cell adhesion molecule: 1 expression in human endothelial cells. Circulation. 1999;99:3125-31.
12. Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res. 2005;51:85-94.
13. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning chromosomal mapping and functional characterization of the human PPAR. Biochemistry. 1993; 32:5598-604.
14. Spiegelman BM, Flier JS. Identification, characterization, and tissue distribution of human PPAR isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. Curr Opin Cell Biol. 1996;87: 377-89.
15. Singh JP, Kauffman R, Bensch W, Wang G, McClelland P, Bean J, et al. Identification of a novel selective PPARα agonist 2-methyl-2-(4-{3-[1-(4methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy) propanoic acid (LY518674) that produces marked changes in serum lipids and apolipoprotein A-1 expression. Mol Pharmacol. 2005; 68;763-8.
16. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation.1998;98:2088-93.
17. Cabrero A, Llaverias G, Roglans N, Alegret M, Sanchez R, Adzet T, et al. Uncoupling protein-3 mRNA levels are increased in white adipose tissue and skeletal muscle of bezafibrate-treated rats. Biochem Biophys Res Commun. 1999;260:547-56.
18. Manojit Pal and Sivaram Pillarisetti. HDL Elevators and Mimetics: Emerging Therapies for Atherosclerosis. Cardiovascular & Hematological Agents in Medicinal Chemistry. 2007; 5: 55-66.
19. Bocher, V., Chinetti, G., Fruchart, J.C., Staels, B. Role of the peroxisome proliferator-activated receptors (PPARs) in the regulation of lipids and inflammation control. J. Soc. Biol. 2002;196:47-52.
20. Fu, J., Gaetani, S., Oveisi, F., Lo Verme, J., Serrano, A., Rodriguez De Fonseca, F., Rosengarth, A., Luecke, H., Di Giacomo, B., Tarzia, G., Piomelli, D.Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature. 2003; 425:90-93.
21. Plutzky J. The potential role of Peroxisome Proliferator-Activated Receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol. 2003;92:34-41.
22. Plotnick G, Corretti M, Vogel R. Effect of antioxidant vitamins on the transient impairment of endothelium dependent brachial artery vasoactivity following a single high fat meal. JAMA. 1997;278:1682-6.
23. Young-Ran Kang, MD, Choong-Hwan Kwak, MD and Jin-Yong Hwang, MD. Safety and Efficacy of Peroxisome Proliferator-Activated Receptor-αAgonist for Treating Cardiovascular Disease. Korean Circ J. 2007;37:599-608.
24. Biscetti F, Gaetani E, Flex A, Aprahamian T, Hopkins T, Straface G, Pecorini G, Stigliano E, Smith RC, Angelini F, Castellot JJ Jr, Pola R. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through avascular endothelial growth factor-dependent mechanism. Diabetes. 2008;57:1394 –1404.
25. Biscetti F, Gaetani E, Flex A, Straface G, Pecorini G, Angelini F, Stigliano E, Aprahamian T, Smith RC, Castellot JJ, Pola R. Peroxisome Proliferator-Activated Receptor-alpha is crucial for iloprost-induced in vivo angiogenesis and VEGF upregulation. J Vasc Res. In press.
26. Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, et al. A tailored therapy for the metabolic syndrome: The dual Peroxisome Proliferator-Activated Receptor-α/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes. 2002;51:1083-7.
27. Bays HE, Stein EA. Pharmacotherapy for dyslipidemia: current therapies and future agents. Pharmacotherapy. 2003; 4:1901–38.
28. Bodkin NL, Pill J, Meyer K, Hansen BC. The effects of K-111, a new insulin-sensitizer on metabolic syndrome in obese prediabetic rhesus monkeys. Horm Metab Res. 2003;35:617–24.
29. Shearer BG, Hoekstra WJ. Recent advances in peroxisome proliferator-activated receptor science. Curr Med Chem. 2003;10:267-80.
30. Kenichi Yoshida. Proof of Evidence: PPAR-induced ANGPTL4 in Lipid and Glucose Metabolism. Biotechnology and Molecular Biology Review. 2007;1:4:105-107.
31. VS Reddy, RK Sahay, SK Bhadada, JK Agrawal, NK Agrawal. Newer Oral Antidiabetic Agents. Journal, Indian Academy of Clinical Medicine. 2000;13:245-251.
32. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, et al. A potent antidiabetic thiazolidinedione with unique Peroxisome Proliferator-Activated Receptor γ-activating properties. J Biol Chem. 1998;273: 32679-84.
33. Fukui Y, Masui S, Osada S, Umesono K, Motojima K. A new thiazolidinedione, NC-2100, which is a weak PPARγ activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes. 2000;49:759-67.
34. Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, Mais DE, et al. A selective Peroxisome Proliferator-Activated Receptor-{gamma} (PPAR {gamma}) modulator blocks adipocyte Differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol. 2000;14:1425-33.
35. Grossman SL, Lessem J. Mechanisms and clinical effects of thiazolidinediones. Expert Opin Invest Drugs. 1997;6:1025-40.
36. Sakamoto, J. et al., Biochem. Biophys.Res. Commun. 2000;278:704–711.
37. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance any type II diabetes. Diabetes. 1996; 45:1661-9.
38. Salwa Sokkar, Jehan A. El-Sharnouby, Amal Helmy, Amal El-Bendary, Laila Sayed Ahmad, Kamal Okasha. Role of Peroxisome Proliferator Activated Receptor gamma2 (PPAR-γg2) Gene Polymorphism in Type 2 Diabetes Mellitus. Eur J Gen Med. 2009;6:2:78-86.
39. Goya K, Sumitani S, Xu X, et al. Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2004; 24:4:658-663.
40. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome Proliferator-Activated Receptor γ ligands inhibit development of atherosclerosis in LDL receptor deficient mice. J Clin Invest. 2000;106:523-31.
41. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, et al. Terminal differentiation of human liposarcoma cells induced by ligands for Peroxisome Proliferator-Activated Receptor γ and the retinoid X receptor. Proc Natl Acad Sci USA. 1997;94:237-41.
42. Minamikawa J, Yamauchi M, Inoue D, Koshiyama H. Another potential use of troglitazone in noninsulin dependent diabetes mellitus. J Clin Endocrinol Metab. 1998;83:1041-2.
43. Staels B. PPARγ & atherosclerosis. Curr Med Res Opin. 2005;21:13-20.
44. Nathalie Hennuyer, Anne Tailleux, Ge´rard Torpier, Hafid Mezdour, Jean-Charles Fruchart, Bart Staels, Catherine Fie´vet. PPARα, but not PPARγ, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia. Arterioscler Thromb Vasc Biol. September 2005. 1897-1902.
45. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161-71.
46. Debril MB, Renaud JP, Fajas L, Auwerx J. The pleiotropic functions of Proxisome Poliferator-Ativated Rceptor γ. J Mol Med. 2001;79:30-47.
47. Jiang C, Ting AT, Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-6.
48. Ricote M, Huang JT, Welch JS, Glass CK. The Peroxisome Proliferator-Activated Receptor γ (PPARγ) as a regulator of monocyte/macrophage function. J Leukoc Biol. 1999;66:733-9.
49. Pasceri V, Wu HD, Willerson JT, Yeh ETH. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 2000; 101: 235-238.
50. Guang-Dong Pan, Hong Wu, Jiang-Wen Liu, Nan-Sheng Cheng, Xian-Ze Xiong, Sheng-Fu Li, Guo-Fu Zhang, Lu-Nan Yan. Effect of peroxisome proliferator-activated receptor-gamma ligand on inflammation of human gallbladder epithelial cells. World J Gastroenterol. 2005;14:11:38:6061-65.
51. Devrim Bozkurt, Hüseyin Taskin, Murat Sezak, Selahattin Biçak, Sait Sen, Ercan Ok, Soner Duman. Rosiglitazone, a Peroxisome Proliferator–Activated Receptor Agonist, Improves Peritoneal Alterations Resulting from an Encapsulated Peritoneal Sclerosis Model. Advances in Peritoneal Dialysis. 2008;24:32-38.
52. Collins AR, Meechan WP, Kintscher U, Jackson S, Wakino S, Noh G, et al. Troglitazone inhibits formation of early atheroscerotic lesions in diabetic and nondiabetic low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:365-71.
53. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1998;1:465-70.
54. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARδ. Nat Med. 1998;4:1046-52.
55. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, et al. Inhibition of human lung cancer cell growth by the Peroxisome Proliferator-Activated Receptor γ agonists through induction of apoptosis. Biochem Biophys Res Commun. 2000;270:400-5.
56. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al. Ligand for Peroxisome Proliferator-Activated Receptor γ (troglitazone) has potent anti-tumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998;58:3344-52.
57. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of Peroxisome Proliferator-Activated Receptor γ (PPARγ) in human transitional bladder cancer and its role in inducing cell death. Neoplasia. 1999;1:330-9.
58. Takahashi GN, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y, et al. Activation of PPARγ inhibit cell growth and induce apoptosis in human gastric cancer cells. FEBS Lett. 1999;455:135-9.
59. Demetri GD, Fletcher CDM, Mueller E, Sarraf P, Naujoks R, Campbell N, et al. Induction of solid tumor differentiation by the Peroxisome Proliferator-Activated Receptor ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA. 1999; 96:3951-6.
60. Stephan Schmidt, Edin Moric, Martina Schmidt, Magdalena Sastre, Douglas L. Feinstein, and Michael T. Heneka. Anti-inflammatory and antiproliferative actions of PPAR γ agonists on T lymphocytes derived from MS patients. J. Leukoc.Biol. 2004;75: 478–485.
61. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse Peroxisome Proliferator-Activated Receptor γ(δ). Mol Cell Biol. 2000;20:5119-28.
62. Berger J., Moller D. E. The mechanisms of action of PPARs. Annu. Rev. Med. 2002;53: 409–435.
63. Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket K, Bodkin NL, et al. A selective Peroxisome Proliferator-Activated Receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA. 2001;98:5306-11.
64. Barry G. Shearer and William J. Hoekstra. Peroxisome Proliferator-Activated Receptors (PPARs): Choreographers of Metabolic Gene Transcription. Celltransmissions. 2003;18: 3-10.
65. Hansen JB, Zhang H, Rasmussen TH, Petersen RK, Flindt EN, Kristiansen K. Peroxisome Proliferator-Activated Receptor γ (PPARγ)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signalling. J Biol Chem. 2001;276:3175-82.
66. Jackson SM, Demer LL. Peroxisome Proliferator-Activated Receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett. 2000;471:119-24.
67. Ehrmann J Jr, Vavrusova N, Collon Y, Kolar Z. Peroxisome Proliferators-Activated Receptors (PPARs) in health and disease. Biomed Papers. 2002;146:11-14.
68. Pershadsingh HA, Heneka MT, Saini R, Amin NM, Broeske DJ, Feinstein DL. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis.J Neuroinflammation. 2004;1:3-7.
69. Kim, E.J., Kwon, K.J., Park, J.Y., Lee, S.H., Moon, C.H. and Baik, E.J. Brain Res. 2002; 941:1–10.
70. Suzanne M. de la Monte, M.D., M.P.H. and Jack R. Wands, M.D. Alzheimer’s Disease Is Type 3 Diabetes—Evidence Reviewed. J Diabetes Sci Technol. 2008;2:6:1101-1113.
71. Nelly billoni, Bruno buan, Brigitte gautier, Christine collin, Olivier gaillard,yann f. Mahea and bruno a. Bernard. Expression of peroxisome proliferator activated receptors (ppars) in human hair follicles and ppara involvement in hair growth. LActa Derm Venereol. 2000; 80: 329-334.
72. Editorial. Peroxisome Profilerator-Activated Receptors (PPARs): The New Frontiers in the Treatment of Cardiovascular Diseases. Tropical Journal of Pharmaceutical Research. 2009;8:2:101-103.
73. Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C, et al. A Peroxisome Proliferator-Activated Receptor α/γ dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Mol Endocrinol. 2005;19:1593-605.
74. Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE, et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARγ. Nature. 2002;415:813-7.
75. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, et al. The structure-activity relationship between Peroxisome Proliferator Receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 1996;39:665-8.
76. Galida–Dual PPAR agonist for type 2 diabetes and metabolic syndrome. Available from: http://www.drugdevelopment-technology.com.
77. Tenenbaum A, Motro M, Fisman EZ. Dual and Pan-Peroxisome Proliferator-Activated Receptors (PPAR) co-agonism: The bezafibrate lessons. Cardiovasc Diabetol. 2005;4:14.
78. Perlecan Pharma’s DRL 11605 enters Phase I clinical trials. Available from: http://www.expresspharmaonline.com.
79. Xu Y, Etgen GJ, Broderick CL, et al. Design and Synthesis of Dual Peroxisome Proliferator-Activated Receptors gamma and delta Agonists as Novel Euglycemic Agents with a Reduced Weight Gain Profile. J Med Chem. 2006; 49:19:5649-5652.
80. FDA Web site: Preclinical and clinical safety assessments for PPAR agonists. 2004; http://www.fda.gov/cder/present/DIA2004/Elhage.ppt.
81. Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab. 2001;27: 305-13.
82. Berger JP, Akiyama TE, Meinke PT. PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol Sci. 2005;26:244-51.
83. Ehrmann J Jr, Vavrusova N, Collon Y, Kolar Z. Peroxisome Proliferators Activated Receptors (PPARs) in health and disease. Biomed Papers. 2002;146:11-14.
84. M. Balasubramanyam and V. Mohan. Current concepts of PPAR-g signaling in diabetes Mellitus. Current Science. 2000;79:10:1440-46.
85. Holden PR, Tugwood JD. Peroxisome Proliferator-Activated Receptor alpha: role in rodent liver cancer and species differences. J Mol Endocrinol. 1999; 22:1-8.